330,831 Shares in Caribou Biosciences, Inc. $CRBU Bought by Nuveen LLC

Key Points

• Nuveen LLC has made a new investment of approximately $302,000 in Caribou Biosciences, acquiring 330,831 shares in the first quarter.
• Caribou Biosciences has received a rating upgrade from sell to hold from Wall Street Zen, with three analysts currently rating it as a buy.
• In its most recent earnings report, Caribou reported a revenue of $2.67 million, exceeding the estimated $1.64 million.

Nuveen LLC purchased a new stake in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 330,831 shares of the company's stock, valued at approximately $302,000. Nuveen LLC owned 0.36% of Caribou Biosciences as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Two Sigma Advisers LP increased its position in Caribou Biosciences by 39.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company's stock valued at $2,338,000 after acquiring an additional 416,600 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in Caribou Biosciences in the 4th quarter valued at approximately $1,921,000. Two Sigma Investments LP increased its position in Caribou Biosciences by 23.7% in the 4th quarter. Two Sigma Investments LP now owns 1,118,696 shares of the company's stock valued at $1,779,000 after acquiring an additional 214,239 shares during the period. Millennium Management LLC increased its position in Caribou Biosciences by 52.9% in the 4th quarter. Millennium Management LLC now owns 859,825 shares of the company's stock valued at $1,367,000 after acquiring an additional 297,351 shares during the period. Finally, Northern Trust Corp increased its position in Caribou Biosciences by 3.4% in the 4th quarter. Northern Trust Corp now owns 714,737 shares of the company's stock valued at $1,136,000 after acquiring an additional 23,531 shares during the period. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Caribou Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday, August 24th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $6.67.

Caribou Biosciences Stock Performance

Shares of NASDAQ:CRBU traded up $0.13 during trading on Thursday, reaching $1.91. The stock had a trading volume of 577,605 shares, compared to its average volume of 724,047. The stock has a market cap of $177.86 million, a price-to-earnings ratio of -1.07 and a beta of 2.54. Caribou Biosciences, Inc. has a 52 week low of $0.66 and a 52 week high of $3.00. The firm's fifty day moving average is $1.90 and its 200 day moving average is $1.32.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. The business had revenue of $2.67 million for the quarter, compared to analyst estimates of $1.64 million. Caribou Biosciences had a negative net margin of 1,800.93% and a negative return on equity of 62.35%. On average, research analysts forecast that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.